Vaderis Announces Positive Clinical Proof-of-Concept Study in HHT Page 1

• Trial delivers positive results in first industry-led clinical trial in hereditary hemorrhagic telangiectasia (HHT)
• VAD044 demonstrated favorable safety and tolerability, along with exploratory efficacy in the major manifestations of the disease
• Data from the ongoing Open Label Extension (OLE) beyond 6 months demonstrate consistent safety, tolerability and continued improvement in bleeding parameters

BASEL, Switzerland, August 27, 2024 /PRNewswire/ — Vaderis Therapeutics AG (Vaderis), a clinical-stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announced positive results from its randomized, double-blind, dose-ranging, placebo-controlled Proof-of-Concept (POC) clinical study in patients suffering from HHT.